|
1
|
Heintz AP, Odicino F, Maisonneuve P, et
al: Carcinoma of the ovary. FIGO 26th annual report on the results
of treatment in gynecological cancer. Int J Gynecol Obstet.
95:S161–S192. 2006.PubMed/NCBI
|
|
2
|
Hardwick KG: Checkpoint signaling: Mad2
conformers and signal propagation. Curr Biol. 15:R122–R124. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lopez-Girona A, Furnari B, Mondesert O and
Russell P: Nuclear localization of Cdc25 is regulated by DNA damage
and a 14-3-3 protein. Nature. 397:172–175. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wang X, Jin DY, Ng RW, Feng H, Wong YC,
Cheung AL and Tsao SW: Significance of MAD2 expression to mitotic
checkpoint control in ovarian cancer cells. Cancer Res.
62:1662–1668. 2002.PubMed/NCBI
|
|
5
|
Li R and Murray A: Feedback control of
mitosis in budding yeast. Cell. 66:519–531. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Orr-Weaver TL and Weinberg RA: A
checkpoint on the road to cancer. Nature. 392:223–224. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yoon DS, Wersto RP, Zhou W, Chrest FJ,
Garret ES, Kwon TK and Gabrielson E: Variable levels of chromosomal
instability and mitotic spindle checkpoint defects in breast
cancer. Am J Pathol. 161:391–397. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lengauer C, Kinzler KW and Vogelstein B:
Genetic instability in colorectal cancer. Nature. 386:623–627.
1997. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lengauer C, Kinzler KW and Vogelstein B:
Genetic instability in human cancer. Nature. 396:643–649. 1998.
View Article : Google Scholar
|
|
10
|
Sotillo R, Hernando E, Diaz-Rodriguez E,
Teruya-Feldstein J, Cordon-Cardo C, Lowe SW and Benezra R: Mad2
overexpression promotes aneuploidy and tumorigenesis in mice.
Cancer Cell. 11:9–23. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Li GQ, Li H and Zhang HF: Mad2 and p53
expression profiles in colorectal cancer and its clinical
significance. World J Gastroenterol. 9:1972–1975. 2003.PubMed/NCBI
|
|
12
|
Wang L, Yin F, Du Y, Du W, Chen B, Zhang
Y, Wu K, Ding J, Liu J and Fan D: MAD2 as a key component of
mitotic checkpoint: A probable prognostic factor for gastric
cancer. Am J Clin Pathol. 131:793–801. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chen X, Cheung ST, So S, et al: Gene
expression patterns in human liver cancers. Mol Biol Cell.
13:1929–1939. 2002. View Article : Google Scholar PubMed/NCBI
|
|
14
|
Yu L, Guo WC, Zhao SH, Tang J and Chen JL:
Mitotic arrest defective protein 2 expression abnormality and its
clinicopathologic significance in human osteosarcoma. APMIS.
118:222–229. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang SH, Xu AM, Chen XF, Li DH, Sun MP
and Wang YJ: Clinicopathologic significance of mitotic arrest
defective protein2 overexpression in hepatocellular carcinoma. Hum
Pathol. 39:1827–1834. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Nakano Y, Sumi T, Morishita M, Fukuda T,
Nobeyama H, Yoshida H, Matsumoto Y, Yasui T and Ishiko O: Mitotic
arrest deficiency 2 induces carcinogenesis in mucinous ovarian
tumors. Oncol Lett. 3:281–286. 2012.PubMed/NCBI
|
|
17
|
Wang X, Jin DY, Wong YC, Cheung AL, Chun
AC, Lo AK, Liu Y and Tsao SW: Correlation of defective mitotic
checkpoint with aberrantly reduced expression of MAD2 protein in
nasopharyngeal carcinoma cells. Carcinogenesis. 21:2293–2297. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Fung MK, Cheung HW, Ling MT, Cheung AL,
Wong YC and Wang X: Role of MEK/ERK pathway in the MAD2-mediated
cisplatin sensitivity in testicular germ cell tumor cells. Br J
Cancer. 95:475–484. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Cheung HW, Chun AC, Wang Q, Deng W, Hu L,
Guan XY, Nicholls JM, Ling MT, Chuan Wong Y, Tsao SW, et al:
Inactivation of human MAD2B in nasopharyngeal carcinoma cells leads
to chemosensitization to DNA-damaging agents. Cancer Res.
66:4357–4367. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sinicrope FA, Ruan SB, Cleary KR, Stephens
LC, Lee JJ and Levin B: Bcl-2 and p53 oncoprotein expression during
colorectal tumorigenesis. Cancer Res. 55:237–241. 1995.PubMed/NCBI
|
|
21
|
Wu CW, Chi CW and Huang TS: Elevated level
of spindle checkpoint MAD2 correlates with cellular mitotic arrest,
but not with aneuploidy and clinicopathological characteristics in
gastric cancer. World J Gastroenterol. 10:3240–3244.
2004.PubMed/NCBI
|
|
22
|
Schvartzman JM, Duijf PH, Sotillo R, Coker
C and Benezra R: Mad2 is a critical mediator of the chromosome
instability observed upon Rb and p53 pathway inhibition. Cancer
Cell. 19:701–714. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Sotillo R, Schvartzman JM, Socci ND and
Beneztra R: Mad2-induced chromosome instability leads to lung tumor
relapse after oncogene withdrawal. Nature. 464:436–440. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhou J, Yao J and Joshi HC: Attachment and
tension in the spindle assembly checkpoint. J Cell Sci.
115:3547–3555. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Buke DJ and Stukenberg PT: Linking
kinetochoremicrotubule binding to the spindle checkpoint. Dev Cell.
14:474–479. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
McGrogan BT, Gilmartin B, Carney DN and
McCann A: Taxanes, microtubules and chemoresistant breast cancer.
Biochim Biophys Acta. 1785:96–132. 2008.PubMed/NCBI
|
|
27
|
Prencipe M, Fitzpatrick P, Gorman S,
Tosetto M, Klinger R, Furlong F, Harrison M, O'Connor D, Roninson
IB, O'Sullivan J and McCann A: Cellular senescence induced by
aberrant MAD2 levels impacts on paclitaxel responsiveness in vitro.
Br J Cancer. 101:1900–1908. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hao X, Zhou Z, Ye S, Zhou T, Lu Y, Ma D
and Wang S: Effect of Mad2 on paclitaxel-induced cell death in
ovarian cancer cells. J Huazhong Univ Sci Technolog Med Sci.
30:620–625. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Du Y, Yin F, Liu C, Hu S, Qang J, Xie H,
Hong L and Fan D: Depression of Mad2 inhibits apoptosis of gastric
cancer cells by upregulating Bcl-2 and interfering mitochondrion
pathway. Biochem Biophys Res Commun. 345:1092–1098. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Morishita M, Sumi T, Nakano Y, Fukuda T,
Nobeyama H, Yoshida H, Matsumoto Y, Yasui T and Ishiko O:
Expression of mitotic-arrest deficiency 2 predicts the efficacy of
neoadjuvant chemotherapy for locally advanced uterine cervical
cancer. Exp Ther Med. 3:341–346. 2012.PubMed/NCBI
|
